Cargando…

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy

Detalles Bibliográficos
Autores principales:	Shao, Xinxin, Ma, Fuhai, Kang, Wenzhe, Xiong, Jianping, Hu, Haitao, Li, Weikun, Xie, Yibin, Tian, Yantao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431543/ https://www.ncbi.nlm.nih.gov/pubmed/37365146 http://dx.doi.org/10.1097/CM9.0000000000002682

Ejemplares similares

Is adjuvant chemotherapy necessary for patients with ypT0–2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?
por: Lu, Zhao, et al.
Publicado: (2018)

Oncologic effects of adjuvant chemotherapy in patients with ypT0–2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis
por: Ha, Gi Won, et al.
Publicado: (2020)

Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital
por: Galata, Christian, et al.
Publicado: (2018)

Evaluating the benefit of adjuvant chemotherapy in patients with ypT0–1 rectal cancer treated with preoperative chemoradiotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
por: Su, Pengfei, et al.
Publicado: (2022)

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
por: Kim, Chang Gon, et al.
Publicado: (2017)

Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer
por: Naiken, Surennaidoo P, et al.
Publicado: (2014)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

Multiple brain metastases in a patient with ypT0N0 micropapillary urothelial carcinoma of the bladder
por: Kuppa, Srikar, et al.
Publicado: (2021)

Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy
por: Trotsyuk, Iryna, et al.
Publicado: (2019)

ypT0 gastric carcinoma after preoperative chemotherapy: a unique status according to AJCC 8(th) edition cancer staging system
por: Zhu, Kankai, et al.
Publicado: (2020)

A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?
por: Celik, Sebahattin, et al.
Publicado: (2015)

YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer
por: Wan, Jue-feng, et al.
Publicado: (2015)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Predicting stage ypT0–1N0 for nonradical management in patients with middle or low rectal cancer who undergo neoadjuvant chemoradiotherapy: a retrospective cohort study
por: Lee, Jeehye, et al.
Publicado: (2022)

PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2018)

The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes
por: Cho, Won Kyung, et al.
Publicado: (2019)

The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis
por: Wang, Ke, et al.
Publicado: (2021)

The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
por: Yang, Tian, et al.
Publicado: (2023)

Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery
por: Kong, Min, et al.
Publicado: (2020)

Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis
por: Jung, Sung Min, et al.
Publicado: (2016)

Comparison between Local Excision and Radical Resection for the Treatment of Rectal Cancer in ypT0-1 Patients: An Analysis of the Clinicopathological Factors and Survival Rates
por: Oh, Soo Young, et al.
Publicado: (2021)

The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Cui, Jian, et al.
Publicado: (2017)

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Cui, Jian, et al.
Publicado: (2019)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study
por: Peltrini, Roberto, et al.
Publicado: (2022)

Is subtotal gastrectomy feasible for the treatment of gastric stump cancer located at the anastomotic site after distal gastrectomy for benign lesions?
por: Ma, Fuhai, et al.
Publicado: (2020)

Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A “Less Is More” Question When ypN0 Is Achieved
por: Liu, Zining, et al.
Publicado: (2021)

Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: A retrospective clinical study
por: Zhong, Yuxin, et al.
Publicado: (2023)

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
por: Fukada, Ippei, et al.
Publicado: (2016)

Can Elevated Pretreatment Serum Carcinoembryonic Antigen Levels Serve as a Potential Biomarker Guiding Adjuvant Chemotherapy in Rectal Cancer Patients With ypTis-3N0 After Neoadjuvant Radiotherapy and Surgery?
por: Huang, Chi, et al.
Publicado: (2021)

Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles
por: Zhong, Yuxin, et al.
Publicado: (2020)

The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
por: Dai, Yuran, et al.
Publicado: (2023)

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2022)

Impact of Adjuvant Chemotherapy Completion on Oncologic Outcomes in ypTNMstage 2 Rectal Cancer Patients
por: Park, Youn Young, et al.
Publicado: (2019)

Peking prognostic score is a useful prognostic factor in patients with gastric cancer liver metastases receiving hepatectomy
por: Xiong, Jianping, et al.
Publicado: (2022)

Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
por: Serrano, Mariana, et al.
Publicado: (2022)

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy
por: Xu, Quan, et al.
Publicado: (2022)

Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer
por: Takashima, Yusuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6evfhdm8615pippan3laom7895